The Exclusion of Patients with CKD in Prospectively Registered Interventional Trials for COVID-19-a Rapid Review of International Registry Data.
journal contributionposted on 29.09.2020, 08:42 by Rupert Major, Haresh Selvaskandan, Yahya Mostafa Makkeyah, Katherine Hull, Apexa Kuverji, Matthew Graham-Brown
The exclusion of patients with CKD from clinical trials has been a barrier to therapeutic advancement in CKD for the last two decades.1 These inequities were highlighted by the Kidney Disease Improving Global Outcomes Controversies Conference, with the ambition of ensuring that individuals with CKD are included in relevant clinical trials.2 The coronavirus disease 2019 (COVID-19) pandemic’s global effect has led to rapid clinical trial registration and commencement in search of effective treatments. Individuals with CKD are at higher risk of COVID-19–related mortality.3 It is unclear, however, if these individuals have equitable access to clinical trial recruitment. Therefore, we aimed to assess the CKD-related inclusion and exclusion criteria for COVID-19 trials.